The Correlation of Antibodies to Nuclear Ribonucleoprotein (RNP) and Nuclear Acidic Protein (Sm) with Nephritis in Patients with Systemic Lupus Erythematosus (SLE)

2015 ◽  
pp. 17-24 ◽  
Author(s):  
N. Kurata ◽  
I. Hara ◽  
M. Kinashi ◽  
H. Akita ◽  
T. Ofuji
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Acidic Protein ◽  
Systemic Lupus ◽  
Nuclear Ribonucleoprotein

scholarly journals Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus

2020 ◽  
Vol 21 (10) ◽  
pp. 3463 ◽  
Author(s):  
Ioannis Parodis ◽  
Emil Åkerström ◽  
Christopher Sjöwall ◽  
Azita Sohrabian ◽  
Andreas Jönsen ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Nuclear Antigen ◽  
Systemic Lupus ◽  
Serum Samples ◽  
Small Nuclear Ribonucleoprotein ◽  
Cytokine Levels ◽  
Nuclear Ribonucleoprotein ◽  
Ribosomal P

We investigated whether belimumab treatment impacts on levels of autoantibodies and cytokines of interest in systemic lupus erythematosus (SLE). Longitudinally collected serum samples from 78 belimumab-treated Swedish SLE patients were analysed. Serum cytokine levels were determined using Luminex xMAP technology, and nuclear antigen autoantibody specificities using addressable laser bead immunoassay. In patients with detectable levels at baseline, interferon (IFN)-α2 levels were lower at month 6 (median; interquartile range (IQR): 8.9; 1.5–54.9 pg/mL) versus baseline (28.4; 20.9–100.3 pg/mL; p = 0.043). Interleukin (IL)-6 (baseline: 7.1; 2.9–16.1 pg/mL) decreased from month 6 (0.5; 0.5–6.3 pg/mL; p = 0.018) and throughout a 24 month follow-up. IL-10 (baseline: 12.6; 2.8–29.7 pg/mL) showed more rapid decreases from month 3 (1.8; 0.6–9.1 pg/mL; p = 0.003). Levels of anti-dsDNA (p < 0.001), anti-Smith antigen (Sm) (p = 0.002), anti-U1 small nuclear ribonucleoprotein (U1RNP) (p < 0.001), anti-Sm-U1RNP complex (p = 0.028), and anti-ribosomal P (p = 0.012) antibodies decreased from month 3 and remained decreased. Anti-Sm positivity at baseline was associated with higher probability and/or shorter time to achieve sustained SLE responder index-4 response (hazard ratio (HR): 2.52; 95% CI: 1.20–5.29; p = 0.015), independently of other factors. Decline of IL-6 levels through month 3 was greater in responders. In summary, belimumab treatment lowered IFN-α2, IL-6, and IL-10 levels, as well as levels of multiple autoantibodies, however after different time spans. Notably, anti-Sm positivity and early decline in IL-6 levels were associated with favorable treatment outcome.

Sign in / Sign up

Export Citation Format

Share Document